share_log

Wedbush Reiterates Outperform on Kura Oncology, Maintains $37 Price Target

Moomoo 24/7 ·  Feb 28 08:08

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $37 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment